We are an oncology-focused biopharmaceutical company dedicated to improving the
lives of cancer patients. We acquire, in-license and develop oncology product
candidates and, if approved for marketing, we intend to commercialize these
products globally. We have in-licensed and are currently developing three
product candidates, rolapitant, niraparib and TSR-011, and in March 2014 we
initiated our immuno-oncology platform strategy by entering into a collaboration
and exclusive license agreement with AnaptysBio, Inc., or AnaptysBio, for the
discovery and development of antibodies for specified immuno-oncology targets.
� Rolapitant is a potent and long-acting neurokinin-1, or NK-1,
receptor antagonist currently in Phase 3 (oral formulation) and Phase 1
(intravenous, or IV, formulation) clinical trials for the prevention of
chemotherapy induced nausea and vomiting, or CINV. In December 2013, we
announced top-line results for two Phase 3 trials of rolapitant.